Kyntra Bio, Inc. KYNB
3.90 USD +0.17 (+4.56%)
At closeNov 9, 2026, 4:04 PM EST
3.90 0.00 0.00%
After hours · Nov 9, 4:04 PM ET
3.77 Day range 3.96
3.60 52-week range 11.19
- YTD
- -55.58%
- 1 year
- -64.64%
- Market cap
- 15.79M
- EPS (ttm)
- -7.64
- YTD return
- -55.58%
- 1-year return
- -64.64%
- Volume
- 11.10K
- Avg volume
- 22.94K
- Open
- 3.86
- Previous close
- 3.73
- Day's range
- 3.77 – 3.96
- 52-week range
- 3.60 – 11.19
5D -0.65 (-14.41%)
Financials — quick view
KYNB Revenue — quarterly -1.47M
KYNB Net income — quarterly 11.97M
KYNB EPS — quarterly 2.96
News
Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35 
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41 
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target - Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate 
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript 
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients - Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30
Your note
Sign in to keep a note on KYNB — it syncs with the Stock Master app.